Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Tiziana Life Sciences Ltd (TLSA : NSDQ)

• Company Description    Tiziana Life Sciences PLC is a biotechnology company. It focuses on the clinical development for the treatment of cancers, chronic inflammatory and autoimmune neurodegenerative disorders. The company's product pipeline consists of Foralumab TZLS-401 and Milciclib TZLS-201 which are in clinical stage. Tiziana Life Sciences PLC is based in London, United Kingdom. Number of Employees: 11

• Price / Volume Information    Yesterday's Closing Price: $0.78 Daily Weekly Monthly 20 Day Moving Average: 82,223 shares Shares Outstanding: 97.31 (millions) Market Capitalization: $76.14 (millions) Beta: 1.21 52 Week High: $2.80 52 Week Low: $0.53 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -17.62% -10.07% 12 Week 17.12% 26.58% Year To Date -18.49% -3.45%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 3RD FLOOR 11-12 ST. JAMES`S SQUARE - LONDON,X0 SW1 4LB GBR ph: 44-20-7495-2379 fax: - info@tizianalifesciences.com http://www.tizianalifesciences.com

• General Corporate Information    Officers Kunwar Shailubhai - Chief Executive Officer; Chief Scientific Officer Gabriele Marco Antonio Cerrone - Chairman Vaseem A. Palejwala - Director; Clinical operations Keeren Shah - Finance Director Jules S. Jacob - Senior Director; CMC & Non-Clinical Development Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: G88912103 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: - Next Expected EPS Date: - Share - Related Items Shares Outstanding: 97.31 Most Recent Split Date: 7.00 (2.50:1) Beta: 1.21 Market Capitalization: $76.14 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.14 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: -

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.54 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - - 12/31/21 - - 09/30/21 - - ROA 03/31/22 - - 12/31/21 - - 09/30/21 - - Current Ratio 03/31/22 - - 12/31/21 - - 09/30/21 - - Quick Ratio 03/31/22 - - 12/31/21 - - 09/30/21 - - Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - - 12/31/21 - - 09/30/21 - - Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Capital 03/31/22 - - 12/31/21 - - 09/30/21 - -

Powered by Zacks Investment Research ©